Few Alzheimer’s patients will be suitable for new disease-modifying therapies, study suggests

Getty/Nadya Tkach

By Lily Canter

Few Alzheimer’s patients will be suitable for new "breakthrough" therapy drugs partly due to poor NHS screening facilities, a study has suggested.

Yet many patients with memory loss will still be referred for disease-modifying drugs lecanemab and donanemab when they become available, said researchers at University College London.